⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IDYA News
IDEAYA Biosciences, Inc. Common Stock
Servier affiche une performance solide en 2024/25 et confirme ses projections pour 2030 USA - Français USA - English USA - English
prnewswire.com
IDYA
Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030 USA - English USA - English USA - Français
prnewswire.com
IDYA
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
prnewswire.com
IDYA
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
prnewswire.com
IDYA
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
prnewswire.com
IDYA
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
prnewswire.com
IDYA
バイオサイトジェンがIDEAYAにライセンスした二重特異性ADC「IDE034」、FDAからIND承認を取得
businesswire.com
IDYA
IDE034, een bispecifiek antilichaam-geneesmiddelconjugaat (ADC) waarvoor Biocytogen een licentie heeft verleend aan IDEAYA, krijgt goedkeuring van de FDA als nieuw onderzoeksgeneesmiddel (IND)
businesswire.com
IDYA
IDE034, ein bispezifisches ADC, das von Biocytogen an IDEAYA lizenziert wurde, erhält IND-Zulassung von der FDA
businesswire.com
IDYA
DE034, un ADC bispecifico concesso in licenza da Biocytogen a IDEAYA, ottiene l’autorizzazione FDA per IND
businesswire.com
IDYA